Table 1.
Baseline characteristics of the intent-to-treat population.
| Hydroxychloroquine + Azithromycin n = 152 |
Hydroxychloroquine n = 152 | Placebo n = 152 |
|
|---|---|---|---|
| Male sex | 150 (98·7%) | 149 (98·0%) | 150 (98·7%) |
| Age (years) | 42 (38–48) | 40 (31–47) | 41 (31–47) |
| Nationality | |||
| Bangladesh | 31 (20·4%) | 32 (21·1%) | 29 (19·1%) |
| Egypt | 0 (0%) | 1 (0·7%) | 0 (0%) |
| Ghana | 5 (3·3%) | 1 (0·7%) | 1 (0·7%) |
| India | 54 (35·5%) | 63 (41·5%) | 47 (30·9%) |
| Indonesia | 0 (0%) | 0 (0%) | 1 (0·7%) |
| Kenya | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
| Nepal | 45 (29·6%) | 38 (25·0%) | 47 (30·9%) |
| Pakistan | 0 (0%) | 1 (0·7%) | 3 (2·0%) |
| Philippines | 7 (4·6%) | 6 (4·0%) | 6 (4·0%) |
| Romania | 0 (0%) | 0 (0%) | 1 (0·7%) |
| Somalia | 0 (0%) | 1 (0·7) | 0 (0%) |
| Sri Lanka | 10 (6·6%) | 6 (4·0%) | 14 (9·2%) |
| Sudan | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
| Uganda | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
| Baseline Ct* | 22·0 (18·4–28·0) | 23·4 (20·0–28·4) | 22·2 (19·2–26·4) |
| Symptoms at enrollment | |||
| Patient-reported fever | 46 (30·3%) | 51 (33·6%) | 52 (34·2%) |
| Respiratory symptoms⁎⁎ | 37 (24·3%) | 36 (23·7%) | 34 (22·4%) |
Data are n (%) or median (IQR).
⁎
Ct=cycle threshold (median for all markers assessed); baseline Ct not available for two participants in hydroxychloroquine group and two participants in placebo group, thus data available for 452 of 456 randomized patients.
⁎⁎
Respiratory symptoms: Chest pain, cough, pharyngitis, or rhinitis.